

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Litteraturliste - Adjuverende kemoterapi ved rectumcancer</b>		
Forfattere:LØP, MY, LW, SEN	Gælder fra 15. juni 2015	Gælder til:

1. Poulsen LØ, Qvortrup C, Pfeiffer P, Yilmaz M, Falkmer U, Sorbye H. Review on adjuvant chemotherapy for rectal cancer – why do treatment guidelines differ so much? *Acta Oncol.* 2015;54:437–36.
2. Russo AL, Borger DR, Szymonifka J, Ryan DP, Wittekind C, Blaszkowsky LS, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. *Cancer* 2014;120:1482–90.
3. Sanz-Pamplona R, Cordero D, Berenguer A, Lejbkowicz F, Rennert H, Salazar R, et al. Gene expression differences between colon and rectum tumors. *Clin Cancer Res* 2011;17:7303–12.
4. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. *Cochrane Database Syst Rev* 2012;3(3):CD004078.
5. Breugom AJ, Swets M, Bosset J, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative ( chemo ) radiotherapy and surgery for patients with rectal cancer : a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 2015;2045:1–8.
6. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet* 2007;370:2020–9.
7. Hamaguchi T, Shirao K, Moriya Y, Yoshida S, Kodaira S, Ohashi Y. Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). *Cancer Chemother Pharmacol.* 2011;67:587–96.
8. Collette L, Bosset J-F, den Dulk M, Nguyen F, Mineur L, Maingon P, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad. *J Clin Oncol* 2007;25:4379–86.
9. Bosset J-F, Collette L. Adjuvant chemotherapy for rectal cancer – Authors' reply. *Lancet Oncol* 2014;15:e197–8.
10. Breugom a. J, van Gijn W, Muller EW, Berglund a., van den Broek CBM, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. *Ann Oncol* 2015;26:696–701.

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Litteraturliste - Adjuverende kemoterapi ved rectumcancer</b>		
Forfattere:LØP, MY, LW, SEN	Gælder fra 15. juni 2015	Gælder til:

11. Tiselius C, Gunnarsson U, Smedh K, Glimelius B, Pahlman L. Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. *Ann Oncol* 2013;24:160–5.
12. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. *J Clin Oncol* 2011;29:2773–80.
13. Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne P-L, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. *J Clin Oncol* 2012;30:4558–65.
14. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. *J Clin Oncol* 2014;32:1927-1934
15. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol* 2012;13:679–87.
16. Rodel C, Liersch T, Fietkau R, Hohenberger W, Graeven U, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. *J Clin Oncol* 2014;32(5s):suppl; abstr 3500.
17. Schmoll H-J, Haustermans K, Price TJ, Nordlinger B, Hofheinz R-D, Daisne J-F, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. *J Clin Oncol* 2014;32(5s):suppl; abstr 3501.
18. Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: Results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control. *Ann Oncol* 2014;25:1356-62
19. Hong YS, Nam B-H, Kim K-P, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label,

DCCG'S NATIONALE RETNINGSLINIER FOR DIAGNOSTIK OG BEHANDLING AF KOLOREKTAL CANCER		
<b>Litteraturliste - Adjuverende kemoterapi ved rectumcancer</b>		
Forfattere:LØP, MY, LW, SEN	Gælder fra 15. juni 2015	Gælder til:

- multicentre, phase 2, randomised controlled trial. *Lancet Oncol* 2014;15:1245–53.
20. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *JAMA* 2011;305:2335–42.
  21. Schmoll H-J, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controll. *Lancet Oncol* 2014;15:1481–92.
  22. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. *J Clin Oncol* 2011;29:1261–70.
  23. Hong SP, Min BS, Kim T II, Cheon JH, Kim NK, Kim H, et al. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. *Eur J Cancer* 2012;48:1235–43.